AB Science SA

1,7380

24-января-25 10:27:39

15 мин. задержка

Акции

-0,0120

-0,69%

Сегодняшний диапазон

1,7300 - 1,7380

ISIN

FR0010557264

Источник

Cboe

AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease

13 мар 2024 06:58:59 Источник Nasdaq GlobeNewswire
AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development

07 мар 2024 08:20:57 Источник Nasdaq GlobeNewswire
AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company

06 мар 2024 13:21:09 Источник Nasdaq GlobeNewswire
AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET

01 мар 2024 11:07:34 Источник Nasdaq GlobeNewswire
AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET

29 фев 2024 04:49:23 Источник Nasdaq GlobeNewswire
AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS

26 фев 2024 11:32:14 Источник Nasdaq GlobeNewswire
AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency

26 янв 2024 11:01:21 Источник Nasdaq GlobeNewswire
AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis

15 янв 2024 11:06:57 Источник Nasdaq GlobeNewswire
AB Science will host a live webcast on Thursday November 30, 2023, from 3pm to 4pm CET, to present the masitinib development program in sickle cell disease

28 ноя 2023 12:22:40 Источник Nasdaq GlobeNewswire
AB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”

27 ноя 2023 01:04:30 Источник Nasdaq GlobeNewswire
AB Science today reports its revenues for the first half of 2023 and provides an update on its activities

29 сен 2023 12:49:30 Источник Nasdaq GlobeNewswire
AB Science provides an update on the EMA timetable for examination of the masitinib marketing authorization application in ALS

18 сен 2023 11:05:35 Источник Nasdaq GlobeNewswire
AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)

26 июн 2023 11:11:42 Источник Nasdaq GlobeNewswire
AB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 2037

01 июн 2023 11:01:02 Источник Nasdaq GlobeNewswire
AB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development Summit

17 май 2023 13:14:57 Источник Nasdaq GlobeNewswire
AB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letter

09 май 2023 11:06:29 Источник Nasdaq GlobeNewswire
AB Science reports its revenues for the year 2022 and provides an update on its activities

28 апр 2023 11:41:27 Источник Nasdaq GlobeNewswire
AB Science - Summary of the presentation on masitinib in ALS delivered at 2023 AAN Annual Meeting

27 апр 2023 13:41:14 Источник Nasdaq GlobeNewswire
AB Science announces the success of its capital increase by private placement for an amount of 15 million euros

24 апр 2023 01:05:09 Источник Nasdaq GlobeNewswire
AB Science announces the implementation of a new strategy and the launch of a capital increase

21 апр 2023 15:26:19 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.